In Brief: Tumor marker downclassification
This article was originally published in The Gray Sheet
Tumor marker downclassification: FDA announces availability of its "Guidance Document for the Submission of Tumor Associated Antigen Pre-Market Notifications, 510(k) to FDA" in the Dec. 17 Federal Register. The agency also codifies in a separate announcement the downclassification of tumor markers used as "an aid in monitoring patients for disease progression or response to therapy or for the detection of recurrent or residual disease" from Class III to Class II ("The Gray Sheet" Sept. 23, 1996, I&W-1). The regulation appears in 21 CFR Section 866.6010...
You may also be interested in...
The AAM has insisted that the US Supreme Court should uphold the inter partes review framework, in an amicus brief filed as part of litigation that potentially threatens hundreds of IPR decisions.
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.